16
robust optimization concept. 22
Materials and methods: 23
To evaluate the feasibility of the robust optimization algorithm on applicator displacements, the clinically applied 24 treatment plans of six tandem and ring (T&R) applicator cases for cervical cancer were included. All patients 25 underwent magnetic resonance imaging (MRI) after the placement of the T&R applicator. The method considered 26 multiple random scenarios reflecting the uncertainties in the dose delivered. For simplicity, the uncertainties in 27 this proof-of-concept study were limited to potential applicator displacements. This problem is optimized by 28 MAD-constrained robust optimization using a patient-specific multi-objective genetic algorithm. The proposed 29 approach is then compared against the nominal (manual) plan strategies. 30 optimization method with a multi-objective genetic algorithm. 100 101 2. Methods 102
2.A. Treatment Planning 103
A set of six MRI planning data sets from patients who had been previously treated with EBRT followed by cervix 104 HDR brachytherapy were used as a representative sample in this study. A planning MRI scan was obtained with 105 a resolution of 0.5 × 0.5 × 4 mm 3 and was completed after insertion tandem-and-ring applicators (T&R) for 106 delivery. All patients received an EBRT dose of 50.40 Gy in 28 fractions and a BT boost dose of 25-30 Gy in 5-6 107 fractions. Target volume delineation, treatment planning, and dose concepts were made in accordance with the 108 GEC-ESTRO recommendations and the EMBRACE protocol guidelines [18, 38, 39] . 109 110
2.B. System Modelling 111
Traditionally, an optimization algorithm needs specific input data such as digitized positions, relevant anatomical 112 structures, and a catheter to calculate a dose distribution matrix. Given the fact that we only used positional 113 information, determining the positional characteristics of the source relative to the calculation of the point dose 114 was completed with care. 115
2.B.1. Object Modelling 116
The contour point-lists for each structure were extracted from the DICOM-RT structure files. As each structure 117 was represented as a set of points per single slice, it meant object shapes could be found in the MR image. Firstly, 118 contour point-lists extracted from the DICOM images were transformed into the patient's coordinates. Next, the 119 convex hull polygon of contour point-lists was resampled in accordance with the MRI image resolution for 120 accurate dose calculation. Then, each resampled slice was inserted into a 3D volume, and the next set of points 121 considered.
Catheter paths were reconstructed independently with application in high-dose-rate brachytherapy. Here, MR 124 compatible T&R applicator sets of two different sized (small and large) rings were used, each with a 30-degree 125 angle, 2.5 mm source position separation, and with a distance from the first source to the applicator tip defined as 126 7 mm. The source dwell positions provided in the applicator coordinate system were defined by the applicator 127 ring structure. 128
2.B.3. Source and Dose Calculation 129
The most widely used radioisotope source for high dose rate (HDR) brachytherapy is 192 Ir. The 192 Ir source has an 130 actual length of 3.5 mm, enclosed within a cylindrical stainless-steel capsule with an external diameter of 1.0 mm 131 ( Figure 1 ). It was loaded by a remote-controlled after-loading system. AAPM TG-43 [40-42] recommended the 132 following formalism for brachytherapy dose calculation using the 192 Ir source: 133 The geometry function is served to account for the inverse square law for point sources, ( , ) is calculated 138 relative to the value on the source transverse plane ( 0 = 90°) at 0 = 1cm. The radial dose function included 139 dose fall-off from the effect of scatter and attenuation but excluded the inverse square-law correction. The 140 anisotropy function represented the variation in dose as a function of polar angle relative to the transverse plane 141 and described the anisotropy due to attenuation within the source. 142 143
2.C. Robust Formulation Concepts 144

2.C.1. Conventional Treatment Plan Optimization 145
We consider robust optimization for EBRT combined with HDR-BT on the minimization of the sum of 146 functions 1 , . . . , . Each treatment plan quality was mathematically defined via an objective function to an 147 anatomical structure and was minimized with respect to some decision variables (dwell times) and χ ⊆ ℝ 148 (the certain feasible set). D ij was the dose deposition coefficient matrix that voxel i received per unit activity of 149 source at dwell position j.
was the set of all voxels inside each contoured structure k under consideration, 150
was the set of all dwell positions, and was the set of all contoured structures. ( ; ) were the constraints to 151 model the impact of the uncertainty of the design, was the uncertain parameter, and ( ) was the set of 152 uncertainty. We formulated the dose distribution matrix of the robust optimization problem for EBRT combined 153 with HDR-BT as follows: 154
The voxel dose was calculated as = ∑ with dose deposition coefficient matrix and dwell times at j 156 dwell positions. In this formula, the tradeoffs related to robustness against the uncertainty across a variety of 157 scenarios was important in order to maximize the dose quality or minimize the error during optimization. If ( ) 158 was empty for all x ∈ χ, then the optimization could be a nominal problem. 159
2.C.2. Types of Uncertainty 160
3D image-based treatment planning with CT or MRI guidance enabled accurate target definition and dose 161 shaping for cervical cancer. However, there were always dosimetric uncertainties where the actual dose delivered 162 was different, for a variety of reasons. The priority ranking of the uncertainties was as follows [43]: 163 1. Uncertainty in dose delivery, including registration of applicator geometry to anatomy (systematic 164 geometry variations). 165 2. Random inter-fraction variations gave rise to a large systematic error, such as significant variations in 166 lung, liver, and rectum. 167
In this study, we were primarily focused on both systematic geometry variations and random inter-fraction 168 variation in each fraction treatment that may give rise to a large applicator displacement. Specifically, repeated 169 applicator insertion during HDR-BT leads to applicator position uncertainty. Consequentially, dosimetric changes 170 occurred in both the target volume and OAR due to applicator shift (i.e., over-or underestimation of doses delivered to the target volume and OAR) [16, 18, 21, 22] . For this study, robust optimization applied to applicator 172 positional uncertainty. 173
2.C.3. Multi-objective and -criteria Robust Method 174
We formulated the multi-criteria robust optimization problem with uncertainty to maximize the fraction of the 175 target volume receiving at least the prescribed dose and to minimize the maximum dose to OAR. (3) 184
As mentioned above, the objective function was to minimize the daily treatment uncertainty for each 185 contoured structure. To account for errors in applicator position, we assumed that the nominal scenario was the 186 treatment plan without considering the shifting position of the applicator (i.e., uncertainty near zero, s = 0). Notice 187 also that displacement of applicators occurs in any direction of the patient coordinate system, ranging from -5.0 188 to +5.0 mm [22]. 189
2.C.3.2. Median Absolute Deviation and Dose Volume Histogram (MAD and DVH) Constraint 190
Accumulate DVHs were the most effective way to describe dose distribution within the target volume or an 191 OAR and is simply referred to as DVH. A DVH displays the percentage of the structure receiving at least a certain dose (i.e., dose covering 90% and 98% of the high-risk clinical target volume (HRCTV), D90, and D98, according 193 to the GEC-ESTRO recommendations). A DVH of the target volumes and OAR for each dose distribution were 194 calculated in all applicator displacement scenarios. DVH parameter function is given by: 195
Where d was the dose in Gy, i indexed the voxels in a given ROI, was the volume of voxel i. Considering Although an extreme outlier could affect the mean and standard deviation of the data, the median and MAD of 200 the data were less liable to an extreme outlier. For that reason, we considered MAD constraint for DVH variation 201 under uncertainties. The median and MAD functions are as follows: 202
Where ̃ was the median value of the DVH curve in a given region of interest (ROI) under uncertainties, , 205
and were a constant linked to the assumption of the normality of the data, disregarding the abnormality induced 206 by outliers, = 1.4826. To control the overshot and undershot to the target volume, we used the function. 207
Using the MAD function as a selection criterion served to protect against the potentially large noise in the 208 uncertainties data [31] . 209
2.C.4. Multi-objective Genetic Algorithm Optimizer 210
In real-world applications, most of the optimization problems involve more than one objective to be optimized 211 simultaneously. This being so, objectives may conflict with each other. A feasible solution to a multi-objective 212 problem was to find a set of solutions. The GAs were well suited to solve multi-objective optimization problems 213 due to a population-based searching approach. The GAs used randomized search optimization techniques inspired 214 by natural evolution, and it used two operators to randomly generate new solutions through variation: crossover parent chromosome generated with a certain crossover probability ( , . . , ). Meanwhile, the 217 mutation operator allowed the exchange of the positions of genes with a certain mutation probability ( ) at two 218 randomly chosen mutation points in a single chromosome. The crossover operator may help the convergence of 219 the population by making the chromosomes alike, and the mutation operator was used to introduce genetic 220 diversity back into the population. After that, the selection was made based on crowding distance. Finally, these 221 selected candidates were then passed on to the next generation. Then, the algorithm proceeds to improve the 222 population through repetitive operations of operators [46] [47] [48] . 223
In this study, given an n-dimensional decision variable vector of dwell times x = { 1 , . . . , } in the solution 224 space , as mentioned above, decision variable vector x was called a chromosome. Normally, the first generation 225 of a chromosome is created randomly and called the initial population. Random generate initial values that were 226 used when solving the problem in this work. To find a vector * that maximized or minimized a given set of k 227 objectives functions F( * ) = { 1 ( * ), . . . , ( * )}, we generated the fitness function that minimized the given 228 objective functions and constraints for our purpose: 229
Where , were objective functions for all contoured organs, and was the prescription dose of the 233 target volume and OAR.
was a MAD function of DVHs of target volume and OAR under uncertainty, and 234 b was a fudge factor that made the MAD values equivalent to the values of standard deviation, b = 1.4826, as 235 previously mentioned above. Then, the constraints of the problem was given by: 236 
RESULTS 250
We have demonstrated what occurs on the curve of the DVH when applicator displacement occurs, and then, 251 the performance of the robust algorithm on generating random sets of applicator displacements in any direction. 252
Finally, we compared the treatment plan between nominal and robust methods. 253
3.A. DVH Variation Under Uncertainty 254
We investigated how DVH curves were changed according to uncertainty in dose delivery by applicator 255 geometry to OARs. With the assumption that the applicator moves randomly in any direction (±5.0 mm below 256 range x, y, and z), the dose variation from applicator positional errors for each target and organ has been plotted 257 (figure 1). We only considered a total of 80 scenarios within a nominal scenario (figure 1) that were chosen 258 randomly. 259 and robust planning for a cervical cancer patient who was treated with an EBRT total dose 5040 cGy, delivered in 263 28 fractions with an ICR total dose of 3000 cGy delivered in five fractions using a T&R applicator. The yellow 264 arrow with a single arrowhead represents the overlap region between the bladder (dark blue color dot line) and 265 TG43 iso-dose line. In all planning, dwell time at each position for desired target coverage was optimized by the 266 previously mentioned three methods. For all planning, the prescription iso-dose line was successfully 267 encompassed based on EMBRACE protocol guidance. As shown in figure 2, we can identify that bladder contour 268 is encompassed by a minimum of percent iso-dose line in the robust planning while maintaining adequate target 269 dose coverage and OAR sparing, rather than both coverage and sparing in the nominal and inverse planning. In 270 figure 3, the cervix brachytherapy plan illustrated the iso-dose line on a coronal view. Figure 3 Figure 4 illustrates the DVH curves from the nominal, inverse, and robust planning for EBRT-BT 293 boost treatment of cervical cancer. The target receives a sufficient dose in all plans, furthermore, improved rectal, 294 sigmoid, bladder, and bowel dose sparing. We found no significant violation of EMBRACE protocol guidance in 295 any DVH parameters of the target volume or OAR using the robust planning. 296 of each target and OAR for nominal, inverse and robust plan strategy. 301 robust planning) was estimated at 85.59 Gy EQD2 , 86.71 Gy EQD2 , and 84.84 Gy EQD2 , respectively, and the 303 standard deviations for each plan were ±1.0177, ±0.9393 and ±0.9085, respectively. Also, the EQD2 and standard 304 deviation of the rectum 2 < 75 * for all plans were also estimated at 55.29 Gy EQD2 (±0.4927), 54.94 Gy EQD2 305 (±0.4620) and 54.09 Gy EQD2 (±0.4052), respectively. Robust planning standard deviations were less than other 306 strategies in both HRCTV and rectum. In this case, in order to show the different dose variations between nominal 307 and robust planning, DVH curves with error scenarios for target and OAR were plotted using colors ( figure 5) . 308
Moreover, although both plans satisfied the requirements for the prescription dose coverage of the target and OAR, 309 the band width of robust DVH curves with error scenarios in all organs were much thinner than the DVHs of the 
3.C. Evaluation of Robust Algorithm with Four Case Sets 319
Further evaluation of our robust strategy compared the plan robustness in the nominal and robust plans (table  320 2). The prepared four case sets of applicator positional errors can be divided into two categories. Two cases (cases 321 2 and 4) were challenging to fit with the EMBRACE protocol guidance, but the other two cases (cases 1 and 3) 322 were a better fit. Table 2 shows the comparison of the EQD2 and the standard deviation values of each strategy. 323
As the above results, this robust strategy could also reduce the standard deviation of target and OAR compared to 324 the nominal plan in most of the cases, whereas the standard deviation of a few organs was not promising. However, 325
the dose delivered results of EQD2 from all cases were optimized delivered doses and also satisfied the EMBRACE protocol guidance related to the target and OAR. Moreover, although the standard deviation in a few 327 organs was not sufficiently minimized, the resulted robustness plans from our strategy might be worth considering 328 according to EMBRACE protocol guidance. In addition, figure 6 demonstrated relative dwell time differences in 329 each case. In the summation of total dwell times, there was not much difference between the two nominal and 330 robust plans. However, we may determine dose differences from the above results. 331 332
DISCUSSION 333
We would like to emphasize that applicator displacement during brachytherapy treatment for cervical cancer 334 lead to radical changes in dose distribution [49] . With the advent of MRI guided EBRT-BT, the opportunity to 335 improve outcomes by increasing the dose while minimizing the dose to OAR is essential in the management of 336 locally advanced cervical cancer. Hence, the applicator displacement uncertainty is of significant relevance within 337 the distribution of dose prescription. Many studies have demonstrated that applicator displacement is a problem 338 of critical importance. Furthermore, applicator shifting and organ movement are inevitable, and it leads to errors in the fractional dose 347 delivery. De Leeuw et al. [16] found geometrical shifts as large as 6 ± 7 mm in the posterior direction. Several 348 studies have previously reported such movements relative to target and organs [16] [17] [18] 23] . While these efforts 349 may reduce required dose delivery and errors, there will always remain residual uncertainties. 350
As mentioned in the above sections, the extreme outlier of the DVH parameter due to random applicator shifting 351 could have occurred. The incorporation of random applicator shifting uncertainty into the robust optimization with the utilization of MAD function enabled the genetic algorithm approach to minimize the extreme outlier. Hence, 353 a robust optimization method with a multi-objective genetic algorithm approach for minimizing dose delivery 354 errors by potential applicator displacement was proposed. Instead of using mean and standard constraints for 355 extreme standard deviations in these scenarios, the MAD function could have found the optimum less affected by 356
outliers. 357
We demonstrated the feasibility of using our robust optimization strategy to minimize potential applicator 358 positional errors with dose delivery variations. The dwell positions and times were determined in a way that 359 mathematically improved the plan quality according to GEC-ESTRO Working Group recommendations. 360
Compared to manual plan approaches, our method resulted in a reduced standard deviation on DVH parameters 361 while maintaining the target dose coverage and sparing OAR. In the complex plan case, we should consider a 362 weighted parameter for each organ to deal with exceptional cases such as overshot and undershot of the target and 363
OAR. 364
Nonetheless, one advantage of the proposed method is that it functions in a similar way to a deep learning approach 365 with given multi-constraints and -objective functions. In addition, it has the ability to avoid being trapped in local 366 optimal solution by searching parallel from a population of points. However, multi-objective function evaluations 367 are often highly time-consuming. Hence, our robust algorithm needs to be used in conjunction with a graphics 368 processing unit (GPU) accelerator to evaluate objective functions and to calculate the dose matrix for each 369 generation. In the future, we aim to develop the proposed in-house accelerating software. 370 371
CONCLUSION 372
Here, we have proposed a robust optimization method with a multi-objective, genetic-algorithm approach 373 using MAD and DVH parameter constraints for minimizing dose delivery errors by potential applicator 374 displacement. The fundamental assumption that only random displacements of applicators were formulated 375 mathematically in terms of objective functions. Subsequently, a mathematical optimization algorithm was used to 376 minimize the objective function value to best meet the planning goals. Finally, the use of this algorithm enabled 377 the minimization of dose delivery errors by potential applicator displacement and acceptable robustness planning. 
